Pages that link to "Q34568130"
Jump to navigation
Jump to search
The following pages link to Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel (Q34568130):
Displaying 50 items.
- Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls (Q26775125) (← links)
- The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19 (Q26801867) (← links)
- Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy (Q26852535) (← links)
- Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection (Q28218540) (← links)
- The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting (Q33776115) (← links)
- Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response (Q33903933) (← links)
- Clopidogrel "resistance": where are we now? (Q34212563) (← links)
- Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro (Q34339780) (← links)
- Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE). (Q35208684) (← links)
- Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke (Q35951677) (← links)
- Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy Ac (Q36036395) (← links)
- Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis (Q36062323) (← links)
- Formation of the thiol conjugates and active metabolite of clopidogrel by human liver microsomes (Q36105504) (← links)
- Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention (Q36334515) (← links)
- Impact of genetic polymorphisms on clinical response to antithrombotics (Q36441477) (← links)
- Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions (Q37027004) (← links)
- Platelet activation, and antiplatelet targets and agents: current and novel strategies. (Q37235603) (← links)
- Balancing potency of platelet inhibition with bleeding risk in the early treatment of acute coronary syndrome. (Q37311337) (← links)
- The genetics of antiplatelet drug resistance (Q37344920) (← links)
- Clopidogrel resistance: pharmacokinetic or pharmacogenetic? (Q37402214) (← links)
- Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting (Q37458916) (← links)
- Recent developments in clopidogrel pharmacology and their relation to clinical outcomes (Q37540088) (← links)
- Proton pump inhibitor and clopidogrel interaction: fact or fiction? (Q37630911) (← links)
- Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans (Q37641606) (← links)
- Does i-T744C P2Y12 Polymorphism Modulate Clopidogrel Response among Moroccan Acute Coronary Syndromes Patients? (Q37651530) (← links)
- Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions (Q37678656) (← links)
- Genetic causes of clopidogrel nonresponsiveness: which ones really count? (Q37697779) (← links)
- Factors associated with clopidogrel nonresponsiveness (Q37709405) (← links)
- Nonresponders to clopidogrel: pharmacokinetics and interactions involved. (Q37786622) (← links)
- Implications of Pharmacogenetic Testing for Patients Taking Warfarin or Clopidogrel (Q37806660) (← links)
- Antiplatelet drug interactions. (Q37809111) (← links)
- Clopidogrel pharmacogenetics: metabolism and drug interactions (Q37912178) (← links)
- The pharmacogenetics of antiplatelet agents: towards personalized therapy? (Q37913976) (← links)
- The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders (Q37923969) (← links)
- Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant? (Q37924323) (← links)
- Genetic and non-genetic factors affecting the response to clopidogrel therapy. (Q37991382) (← links)
- Metabolic differences of current thienopyridine antiplatelet agents (Q38071707) (← links)
- CYP3A5 polymorphism, amlodipine and hypertension (Q38122295) (← links)
- Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran. (Q38148597) (← links)
- Pharmacogenomics of oral antiplatelet drugs. (Q38195628) (← links)
- Clinical pharmacokinetics and pharmacodynamics of clopidogrel (Q38307535) (← links)
- P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use (Q38542096) (← links)
- The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). (Q38750444) (← links)
- Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy. (Q38806725) (← links)
- The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics (Q39249688) (← links)
- Concomitant Use of Proton-Pump Inhibitors and Clopidogrel Increases the Risk of Adverse Outcomes in Patients With Ischemic Stroke Carrying Reduced-Function CYP2C19*2. (Q39380363) (← links)
- Implications of Inter-Individual Differences in Clopidogrel Metabolism, with Focus on Pharmacogenetics (Q39948342) (← links)
- Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease (Q41141258) (← links)
- Comparison of the antiplatelet effect of clopidogrel hydrogenosulfate and clopidogrel besylate in patients with stable coronary artery disease (Q41463098) (← links)
- P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon? (Q41511099) (← links)